title: The puzzle of overactive bladder: controversies, inconsistencies, and insights.
abstract: Overactive bladder (OAB) affects millions of individuals and may severely impair the quality of life of those affected. The contribution of human behavior to manifestations of this symptom complex remains poorly understood. Continued evolution of our understanding of the pathophysiology of OAB has identified contributory mechanisms, which in turn may open new therapeutic avenues. Recent improvements in drug delivery systems represent advances in the management of OAB. However, more complete symptom control with greater tolerability is desirable; this awaits the development of agents specific for newly emerging and as yet unidentified pathophysiologic pathways. Importantly, as understanding of outcomes assessment in OAB matures, refined assessments of disease severity, response to intervention, and patient preference should be possible.
authors.affiliation: Department of Urology, Vanderbilt University School of Medicine, Room A 1302, Medical Center North, Nashville, TN 37232, USA. roger.dmochowski@vanderbilt.edu
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
mesh_terms: D000818:Animals; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009119:Muscle Contraction / Q000502:physiology; D010276:Parasympatholytics / Q000627:therapeutic use; D010349:Patient Compliance; D010665:Phenylpropanolamine / Q000627:therapeutic use; D011788:Quality of Life; D000068737:Tolterodine Tartrate; D001743:Urinary Bladder / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy
chemical_list: D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin